AMORFIX LIFE SCIENCES ANNOUNCES MEMBERSHIP IN ALZHEIMER'S DISEASE
NEUROIMAGING INITIATIVE (ADNI)
TSX: AMF
TORONTO, Oct. 7 /CNW/ - Amorfix Life Sciences announced today that it has accepted an invitation to become a member of the Alzheimer's Disease Neuroimaging Initiative (ADNI). The mission of ADNI is to establish and validate tests for brain images, as well as cerebral spinal fluid and blood biomarkers, as predictors of Alzheimer's disease. Membership in ADNI will provide Amorfix access to leading research in the Alzheimer's field and access to human clinical samples necessary to validate the its A4 assay as a potential human diagnostic test.
"Amorfix developed the A(4) (Amorfix Aggregated ABeta Assay), an ultra-sensitive assay for the detection of aggregated ABeta, to address the need to improve current methods used for identification of potential lead compounds in pre-clinical trials. The promising data obtained from these experiments support future development of the aggregated ABeta peptide as a biomarker for human Alzheimer's disease. We look forward to working with ADNI to develop a diagnostic test to properly identify individuals who have or may develop Alzheimer's disease." said Louise Scrocchi, Associate Director, Research and Development for Amorfix, and Head of the Alzheimer's disease Diagnostic Program.
"Membership in ADNI represents an important step for Amorfix in the development and characterization of our human Alzheimer's disease diagnostic and we are very pleased to join this prestigious organization" said Dr. Robert Gundel, President and CEO of Amorfix. "We will continue to work diligently towards our goal of having a biochemical assay to assist in the accurate diagnosis of Alzheimer's disease, a disease already affecting millions of people around the world and expected to increase tremendously over the next few years. Joining ADNI will greatly assist us in achieving our goal."
About A(4)
The Amorfix A(4) assay is an ultrasensitive method for the detection of aggregated ABeta that provides quantitative measurements of aggregates. The A(4) can detect aggregates in plasma, and brain tissue from standard animal models of AD several months before conventional microscopic procedures thereby accelerating the preclinical screening of new drugs for AD. The A(4) is significantly more sensitive than current methods for detecting total ABeta and can be used in high-throughput applications designed to study the inhibition of amyloid formation.
About Amorfix
Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including Alzheimer's disease, ALS, and cancer. The Company's diagnostic programs include an ultrasensitive method for the detection of aggregated Beta-Amyloid (ABeta) in brain tissue and blood from animal models of AD, months prior to observable amyloid formation, as well as human blood screening tests for Alzheimer's and early liver cancer detection. Amorfix's proprietary Epitope Protection(TM) (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample. Amorfix utilizes its computational discovery platform, ProMIS(TM), to predict novel Disease Specific Epitopes ("DSE") on the molecular surface of misfolded proteins. Amorfix's lead therapeutic programs include antibodies and vaccines to DSEs in ALS, AD and cancer. For more information about Amorfix, visit www.amorfix.com.
Forward-Looking Information
This press release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
%SEDAR: 00022789E
For further information: Dr. Robert Gundel, President & Chief Executive Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6957, Fax: (416) 847-6899, [email protected]; Janet Clennett, Acting Chief Financial Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6926, Fax: (416) 847-6899, [email protected]
Share this article